Sinopharm : ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE SIX MONTHS ENDED 30 JUNE 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on

business in Hong Kong as 國控股份有限公司 )

(Stock Code: 01099)

ANNOUNCEMENT

PRELIMINARY FINANCIAL DATA OF

SINOPHARM ACCORD

FOR THE SIX MONTHS ENDED 30 JUNE 2020

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 17 August 2020 (the "Announcement") in relation to the announcement on preliminary financial data for the six months ended 30 June 2020 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares) (collectively with its subsidiaries, the "Sinopharm Accord Group").

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the six months ended 30 June 2020 (the "Reporting Period") as set out in the Announcement.

1

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Unit: Unless otherwise stated, in RMB 0'000)

	Items			The Reporting			Same period of last year			Change (％)
			Period			Before			After
						adjustment			adjustment			After adjustment
	Total Operating		2,716,994.02	2,522,814.74	2,559,919.88		6.14%
	Revenue
	Operating Profit		101,410.82	95,838.76	95,726.47		5.94%
	Total Profit		101,631.93	96,033.65	95,918.89		5.96%
	Net profit
	attributable to		64,345.16	65,083.34	64,915.44		-0.88%
	shareholders of the
	listed company
	Basic earnings per		1.50	1.52	1.52		-1.32%
	share (RMB)
	Weighted average		4.91%	5.44%	5.38%			decreased by 0.47
	ROE				percentage points
				As at the end			As at the beginning of the			Change (％)
				of the			Reporting Period
				Reporting			Before			After			After adjustment
				Period			adjustment			adjustment
	Total assets		3,766,985.02	3,352,060.91	3,402,884.32		10.70%
	Equity
	attributable to		1,319,998.31	1,280,641.09	1,291,114.04		2.24%
	shareholders of the
	listed company
	Share capital (in		42,812.70	42,812.70	42,812.70		0.00%
	0'000 shares)
	Net assets
	attributable to
	shareholders of the		30.83	29.91	30.16		2.22%
	listed company per
	share (RMB)

Note 1: In 2020, Sinopharm Accord Group acquired 75.00% equity interest in Shanghai Pudong New area Medical Materials Co., Ltd. (上海浦東新區醫藥藥材有限公司, "Shanghai Pudong") which is under the same

control as the Sinopharm Accord Group. When preparing the comparison table of the consolidated financial statements of Sinopharm Accord Group for the first half year of 2020, it is deemed that Sinopharm Accord Group has consolidated the financial statements of Shanghai Pudong from the date when the ultimate controller of the parties to the transaction controlled Shanghai Pudong, and the financial data of the same period last year is so adjusted.

Note 2: The financial data as at the end of the Reporting Period are filled in according to the consolidated financial statements of Sinopharm Accord.

Note 3: The net profit attributable to the shareholders of the listed company for the Reporting Period decreased by 0.88% as compared to the same period last year, which is mainly due to the fact that the growth

2

rate of sales of Sinopharm Accord Group slowed down as affected by the COVID-19 pandemic. The change of the industry policies also narrowed the profitability. As a result, the basic earnings per share has decreased by 1.32% as compared to the same period last year, and the weighted average ROE dropped by 0.47 percentage points as compared to the same period last year.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC

17 August 2020

As at the date of this announcement, the executive Directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive Directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive Directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies
  Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

3